Stephanie Planque

Planque was awarded the Ph.D. degree in 2009 by the University of Texas-Houston Medical School for her advances in applying electrophilic analogs of proteins to decipher the beneficial and harmful functional effects of catabodies. She then expanded her focus to vaccination and therapeutic catabody identification using proprietary electrophilic target analogs. Her work was published in 48 peer-reviewed scientific articles, she has numerous national/international conference presentations, and she was PI in an NIH-funded STTR grant. She moved fulltime as a co-founder to Covalent in 2018 to focus on rapidly translating our electrophilic vaccine/catabody technologies to clinical reality.